Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare ...

BALA CYNWYD, Pa., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare ...

Larimar Therapeutics Inc (LRMR) stock saw a modest uptick, ending the day at $7.14 which represents a slight increase of $0.29 or 4.23% from the prior close of $6.85. The stock opened at $7.08 and ...

BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) is set to present pivotal data from its nomlabofusp Phase 1 and ...

(MENAFN- GlobeNewsWire - Nasdaq) BALA CYNWYD, Pa., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage ...

This page features the latest news about the Larimar Therapeutics Inc stock. Jones Trading sets $14 target on Larimar shares, bullish on FA therapy On Wednesday, Larimar Therapeutics (NASDAQ ...

The Business Research Company's Progressive Ataxia And Weakness Disorders Global Market Report 2024 – Market Size, Trends, And Global Forecast 2024-2033 It will grow to $52.92 billion in 2028 at ...

Denali Therapeutics, Neurogene, Larimar Therapeutics, and Grace Science will be the first companies to benefit from the FDA's higher levels of guidance and advice in areas like clinical trial ...

Larimar Therapeutics Inc (NASDAQ: LRMR)’s stock price has increased by 8.61 compared to its previous closing price of 6.85. However, the company has seen a 2.76% increase in its stock price over the ...

Robert W. Baird has recently initiated Larimar Therapeutics Inc (LRMR) stock to Outperform rating, as announced on September 4, 2024, according to Finviz. Earlier, on April 3, 2024, Leerink Partners ...